Literature DB >> 11920212

The 5TMM series: a useful in vivo mouse model of human multiple myeloma.

K Asosingh1, J Radl, I Van Riet, B Van Camp, K Vanderkerken.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11920212     DOI: 10.1038/sj.thj.6200052

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


× No keyword cloud information.
  49 in total

1.  CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.

Authors:  Sungyoul Hong; Jianfei Qian; Haiyan Li; Jing Yang; Yong Lu; Yuhuan Zheng; Qing Yi
Journal:  Cancer Immunol Immunother       Date:  2011-10-15       Impact factor: 6.968

2.  Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies.

Authors:  M Lemaire; M D'Huyvetter; T Lahoutte; E Van Valckenborgh; E Menu; E De Bruyne; P Kronenberger; U Wernery; S Muyldermans; N Devoogdt; K Vanderkerken
Journal:  Leukemia       Date:  2013-10-09       Impact factor: 11.528

3.  Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.

Authors:  Siqing Wang; Jing Yang; Jianfei Qian; Michele Wezeman; Larry W Kwak; Qing Yi
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

4.  Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.

Authors:  Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke
Journal:  Cancer Lett       Date:  2020-01-31       Impact factor: 8.679

5.  Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells.

Authors:  Karin Vanderkerken; Isabelle Vande Broek; Décio L Eizirik; Els Van Valckenborgh; Kewal Asosingh; Ivan Van Riet; Ben Van Camp
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

6.  Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.

Authors:  S Hong; H Li; J Qian; J Yang; Y Lu; Q Yi
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

7.  Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.

Authors:  Els Van Valckenborgh; Peter I Croucher; Hendrik De Raeve; Chris Carron; Evy De Leenheer; Sylvia Blacher; Laetitia Devy; Agnès Noël; Elke De Bruyne; Kewal Asosingh; Ivan Van Riet; Ben Van Camp; Karin Vanderkerken
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

8.  A murine model of myeloma that allows genetic manipulation of the host microenvironment.

Authors:  Jessica A Fowler; Gregory R Mundy; Seint T Lwin; Conor C Lynch; Claire M Edwards
Journal:  Dis Model Mech       Date:  2009-09-24       Impact factor: 5.758

9.  The effects of forodesine in murine and human multiple myeloma cells.

Authors:  Liesbeth Bieghs; Jo Caers; Elke De Bruyne; Els Van Valckenborgh; Fiona Higginbotham; Karin Vanderkerken; Eline Menu
Journal:  Adv Hematol       Date:  2010-10-19

Review 10.  Myeloid-derived suppressor cells in B cell malignancies.

Authors:  Yaghoub Yazdani; Mousa Mohammadnia-Afrouzi; Mehdi Yousefi; Enayat Anvari; Ghasem Ghalamfarsa; Hadi Hasannia; Sanam Sadreddini; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2015-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.